

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
20 September 2001 (20.09.2001)(10) International Publication Number  
**WO 01/68179 A1**

(51) International Patent Classification<sup>7</sup>: **A61M 25/02**

(21) International Application Number: **PCT/CA01/00304**

(22) International Filing Date: 9 March 2001 (09.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/524,027 13 March 2000 (13.03.2000) US

(71) Applicant (for all designated States except US): **WESTAIM BIOMEDICAL CORP. [CA/CA]; 10102-114 Street, Fort Saskatchewan, Alberta T8L 3W4 (CA).**

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BURRELL, Robert, Edward [CA/CA]; 52055, R.R. 221, Sherwood Park, Alberta T8E 1C6 (CA). YIN, Hua, Qing [CN/CA]; 24 Davy Crescent, Sherwood Park, Alberta T8H 1P3 (CA).**

(74) Agent: **MCKAY-CAREY, Mary, Jane; McKay-Carey & Company, 2590 Commerce Place, 10155-102nd Street, Edmonton, Alberta T5J 4G8 (CA).**

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

## Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

[Continued on next page]

(54) Title: TRANSCUTANEOUS MEDICAL DEVICE DRESSINGS AND METHOD OF USE

**WO 01/68179 A1**

(57) Abstract: A transcutaneous device dressing and method for its use with a transcutaneous medical device, such as an intravascular catheter, which punctures the skin of a patient and which has a portion of the medical device protruding from the skin which can lead to infection. The dressing includes a top and a bottom dressing, both being formed from a flexible material and having upper and lower surfaces, with the lower surface being the skin facing surface in use. The bottom dressing has a slit formed therein extending from one edge inwardly to a termination point within the confines of the bottom dressing. An anti-microbial material is provided without the use of adhesives at the upper and lower surfaces of the bottom dressing, and at least at the lower surface of the top dressing. In use, the bottom dressing is placed next to the skin, the slit allowing the bottom dressing to surround the puncture site such that the lower surface of the bottom dressing is in contact with the skin while the upper surface of the bottom dressing is in contact with a portion of the medical device protruding from the skin. The top dressing is placed above the puncture site such that its lower surface is in contact with a portion of the medical device protruding from the skin. In this way, there is exposure of the portion of the medical device protruding from the skin to the anti-microbial activity of the anti-microbial material.



*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

1                   **"Transcutaneous Medical Device Dressings and Method of Use"**  
23                   **FIELD OF THE INVENTION**4                   The invention relates to transcutaneous medical device dressings, and processes for  
5                   their production and use, for controlling infections.6                   **BACKGROUND OF THE INVENTION**7                   Transcutaneous medical devices are catheters, pins, implants and the like which pass  
8                   through the skin and are indwelling for some considerable time. Exemplary of  
9                   transcutaneous medical devices are central venous catheters, peripheral venous catheters,  
10                  Swan-Ganz pulmonary catheters, central nervous system implants (ex. external ventricular  
11                  drainage and ventricular reservoirs), peritoneal dialysis catheters, such as for continuous  
12                  ambulatory peritoneal dialysis and continuous cyclic peritoneal dialysis, hemodialysis  
13                  catheters, transvenous pacemaker leads and temporary orthopedic pins. All of these  
14                  transcutaneous medical devices, when in place, have a portion of the device which is external,  
15                  that is which is left protruding from the skin, and which can be the cause of infection.16                  The risk of acquiring infections from transcutaneous infections is very high. For  
17                  instance, the risk of acquiring catheter-related bloodstream infection ranges from 0.9 to 8%.  
18                  This nosocomial bloodstream infections cause a case fatality of more than 20%, and account  
19                  for an increase of thousands of dollars in hospital costs per infection, or tens of thousands of  
20                  dollars per survivor in ICU needing an extra week of hospital stay. As for peritoneal dialysis,  
21                  a very experienced center today still has a peritonitis rate of one episode per 15 to 25 patient  
22                  months. The major sources of bacteria in these infections are from surrounding skin.23                  To prevent infections associated with transcutaneous medical devices antiseptic  
24                  preparation of insertion sites, including the initial application of topical anti-microbial  
25                  solutions such as alcohol or iodine to the insertion sites is known. A further topical ointment  
26                  after insertion of the device, such as an ointment containing neomycin, polymyxin and  
27                  bactracin, has been shown to prevent catheter colonization/infection, but it may increase the  
28                  risk of fungal infection. Ointments are also inconvenient, requiring multiple replacements.  
29                  There have also been attempts to attach a cuff to the catheters, with an anti-microbial agent  
30                  impregnated in the cuff. Efforts to coat the catheters with anti-microbial agents are known.  
31                  However, none of these efforts has been completely successful in clinical trials. Presently,  
32                  the most common catheter dressing used in hospitals comprises sterile gauze or polyurethane

1 film, which have limited infection control properties.

2 Recent efforts to replace gauze with a transparent film dressing to allow a visual  
3 check on the insertion site is known, see for instance US Patent No. 5,372,589, issued  
4 December 13, 1994 to Davis. No anti-microbial control is taught with such a dressing.  
5 Johnson & Johnson Medical Inc. markets a product under the trade mark BIOPATCH, which  
6 is a chlorhexidine gluconate-impregnated catheter patch. An Iodophor transparent dressing  
7 has also been suggested. However, to date, no completely effective anti-microbial device for  
8 use with transcutaneous medical devices is known.

9 A securement devices is taught for securing a intravenous device to the body in US  
10 Patent 3,918,446, issued November 11, 1975 to Buttaravoli. The device has an upper and a  
11 lower pad, between which the intravenous device is fixed. Since the function of the device is  
12 to secure the device to the body, there is a teaching to provide an adhesive material to the  
13 bottom of lower pad, and to the bottom of the top pad. There is a mention of providing the  
14 adhesive with an antibacterial agent. This device has the disadvantage of using adhesives  
15 with the antibacterial agent, which limits the effectiveness and long lasting ability of the  
16 antibacterial agent. Furthermore, the adhesive can be irritating next to the skin, cause skin  
17 damage and patient discomfort on removal, and inhibits the removal or changing of the  
18 device. Furthermore, many adhesives act as moisture barriers, which can limit the  
19 effectiveness of the antibacterial agent. Finally, the device of this patent teaches including a  
20 slit in the bottom pad of the dressing, which lies below the intravenous needle or catheter  
21 when the device is in place, allowing the intravenous device to remain in contact with the  
22 skin, and therefore limiting the infection control of the device.

### 23 SUMMARY OF THE INVENTION

24 In one broad aspect, the invention provides a transcutaneous device dressing for use  
25 with a transcutaneous medical device which has punctured the skin of a patient and which has  
26 a portion of the medical device protruding from the skin, comprising:

27 a top and a bottom dressing, both being formed from a flexible material and having  
28 upper and lower surfaces, with the lower surface being skin facing in use;

29 the bottom dressing having a slit formed therein extending from one edge inwardly to  
30 a termination point within the confines of the bottom dressing;

31 an anti-microbial material provided without adhesives at the upper and lower surfaces  
32 of the bottom dressing, and at least at the lower surface of the top dressing;

1       whereby, in use, the bottom dressing is placed next to the skin, the slit allowing the  
2 bottom dressing to surround the puncture site such that the lower surface of the bottom  
3 dressing is in contact with the skin and the upper surface of the bottom dressing is in contact  
4 with a portion of the medical device protruding from the skin, and the top dressing is placed  
5 above the puncture site such that its lower surface is in contact with a portion of the medical  
6 device protruding from the skin, thereby exposing a portion of the medical device protruding  
7 from the skin from above and below to the anti-microbial activity of the anti-microbial  
8 material.

9       In another broad aspect, the invention provides a method of dressing the puncture site  
10 of a transcutaneous medical device to limit infection by microorganisms from the  
11 surrounding skin and the portion of the medical device that protrudes from the skin of a  
12 patient, comprising:

13       providing a transcutaneous device dressing, comprising:  
14       a top and a bottom dressing, both being formed from a flexible material and having  
15 upper and lower surfaces, the lower surfaces being skin facing when the dressing is in use;  
16       the bottom dressing having a slit formed therein extending from one edge inwardly to  
17 a termination point within the confines of the bottom dressing; and  
18       an anti-microbial material provided without the use of adhesives at the upper and  
19 lower surfaces of the bottom dressing, and at least at the lower surface of the top dressing;  
20       sliding the bottom dressing in place next to the skin using the slit to allow the bottom  
21 dressing to surround the puncture site at the termination point such that the lower surface of  
22 the bottom dressing is in contact with the skin surrounding the puncture site while the upper  
23 surface of the bottom dressing is in contact with a portion of the medical device protruding  
24 from the skin;  
25       applying the top dressing above bottom dressing such that its lower surface is in  
26 contact with a portion of the medical device protruding from the skin;  
27       depending on the anti-microbial material, applying a water or alcohol based  
28 electrolyte to the top and bottom dressings to release the anti-microbial agent; and  
29       fixing the top and bottom dressings to the skin, preferably with an occlusive or semi-  
30 occlusive layer such as an adhesive film.

31       The transcutaneous device dressing of this invention has the advantage of ease of  
32 placement and been demonstrated to be much more effective than disc type dressings which

1 are laid flat under the transcutaneous device, which have only a limited portion, generally  
2 only the thickness of the dressing (less than 3 mm), in contact with the portion of the medical  
3 device which protrudes from the skin.

4 Preferably, the dressing of this invention is formed such that the top and bottom  
5 dressings are joined along a fold line, that is they are formed from a unitary dressing which is  
6 folded over in use. The slit is preferably formed from the edge of the bottom dressing which  
7 is parallel to the fold. The dressing is preferably formed from multilayered, laminated  
8 dressing materials. The anti-microbial material is preferably a thin film of an anti-microbial  
9 metal, most preferably formed with atomic disorder so as to create an effective anti-microbial  
10 effect, and to create an interference colour so as to provide an indicator, as described in  
11 WO98/41095, published September 24, 1998, and naming inventors R. E. Burrell and R. J.  
12 Precht.

13 The dressing of this invention has application to transcutaneous medical devices such  
14 as listed above, made from a wide variety of materials, for example metals, including steel,  
15 aluminum and its alloys, latex, nylon, silicone, polyester, polyurethane, and other plastics and  
16 rubbers. Such devices are generally made of a bioinert or Biocompatible material. The  
17 device may take a variety of shapes including rod or tube shapes, hollow or solid, and may be  
18 rigid or flexible, factors dictated by its intended utility.

19 As used herein and in the claims, the terms and phrases set out below have the  
20 meanings which follow.

21 "Metal" or "metals" includes one or more metals whether in the form of substantially  
22 pure metals, alloys or compounds such as oxides, nitrides, borides, sulphides, halides or  
23 hydrides.

24 "Anti-microbial metals" are metals whose ions have an anti-microbial effect.  
25 Preferably, the metal will also be biocompatible. Preferred anti-microbial metals include Ag,  
26 Au, Pt, Pd, Ir (i.e. the noble metals), Sn, Cu, Sb, Bi and Zn, with Ag being most preferred.

27 "Biocompatible" means non-toxic for the intended utility. Thus, for human utility,  
28 biocompatible means non-toxic to humans or human tissues.

29 "Anti-microbial effect" means that atoms, ions, molecules or clusters of the anti-  
30 microbial metal (hereinafter "species" of the anti-microbial metal) are released into the  
31 alcohol or electrolyte which the material contacts in concentrations sufficient to inhibit  
32 bacterial (or other microbial) growth in the vicinity of the material. The most common

1 method of measuring anti-microbial effect is by measuring the zone of inhibition (ZOI)  
2 created when the material is placed on a bacterial lawn. A relatively small or no ZOI (ex. less  
3 than 1 mm) indicates a non useful anti-microbial effect, while a larger ZOI (ex. greater than 5  
4 mm) indicates a highly useful anti-microbial effect. One procedure for a ZOI test is set out in  
5 the Examples which follow.

6 "Sustained release" or "sustainable basis" are used to define release of atoms,  
7 molecules, ions or clusters of an anti-microbial metal that continues over time measured in  
8 hours or days, and thus distinguishes release of such metal species from the bulk metal, which  
9 release such species at a rate and concentration which is too low to achieve an anti-microbial  
10 effect, and from highly soluble salts of anti-microbial metals such as silver nitrate, which  
11 releases silver ions virtually instantly, but not continuously, in contact with an alcohol or  
12 electrolyte.

13 "Atomic disorder" includes high concentrations of: point defects in a crystal lattice,  
14 vacancies, line defects such as dislocations, interstitial atoms, amorphous regions, gain and  
15 sub grain boundaries and the like relative to its normal ordered crystalline state. Atomic  
16 disorder leads to irregularities in surface topography and inhomogeneities in the structure on  
17 a nanometer scale.

18 "Normal ordered crystalline state" means the crystallinity normally found in bulk  
19 metal materials, alloys or compounds formed as cast, wrought or plated metal products. Such  
20 materials contain only low concentrations of such atomic defects as vacancies, grain  
21 boundaries and dislocations.

22 "Diffusion", when used to describe conditions which limit diffusion in processes to  
23 create and retain atomic disorder, i.e. which freeze-in atomic disorder, means diffusion of  
24 atoms and/or molecules on the surface or in the matrix of the material being formed.

25 "Alcohol or water-based electrolyte" is meant to include any alcohol or water-based  
26 electrolyte that the anti-microbial materials of the present invention might contact in order to  
27 activate (i.e. cause the release of species of the anti-microbial metal) into same. The term is  
28 meant to include alcohols, water, gels, fluids, solvents, and tissues containing water,  
29 including body fluids (for example blood, urine or saliva), and body tissue (for example skin,  
30 muscle or bone).

31 "Colour change" is meant to include changes of intensity of light under  
32 monochromatic light as well as changes of hue from white light containing more than one

1 wavelength.

2 An "interference colour" is produced when light impinges on two or more partly  
3 reflective surfaces separated by a distance which bears the right relationship to the  
4 wavelength of the light to be removed by destructive interference.

5 "Partly reflective" when used to describe the base or top layer materials, means that  
6 the material has a surface which reflects a portion of incident light, but which also transmits a  
7 portion of the incident light. Reflection occurs when a ray of incoming light encounters a  
8 boundary or interface characterized by a change in refractive index between two media. For  
9 the top layer of the anti-microbial materials of this invention, that interface is with air. For  
10 the base layer, the interface is with the top layer. The reflectance of the base and top layers is  
11 balanced so as to generate an interference colour.

12 "Partly light transmissive" when used to describe a thin film of the top layer material  
13 means that the thin film is capable of transmitting at least a portion of incident visible light  
14 through the thin film.

15 "Detectable" when used to describe a colour change means an observable shift in the  
16 dominant wavelength of the reflected light, whether the change is detected by instrument,  
17 such as a spectrophotometer, or by the human eye. The dominant wavelength is the  
18 wavelength responsible for the colour being observed.

#### 19 **DESCRIPTION OF THE DRAWINGS**

20 Figure 1 is a schematic sectional figure of a three layer transcutaneous device dressing  
21 in accordance with the present invention;

22 Figure 2 is a schematic perspective view of a three layer transcutaneous device  
23 dressing folded along a central line to form top and bottom dressings and showing the slit for  
24 placement around the transcutaneous medical device;

25 Figure 3 is a schematic sectional view of the folded transcutaneous device dressing in  
26 place with a catheter penetrating the skin of a patient;

27 Figure 4 is a plan view of the transcutaneous device dressing of this invention,  
28 showing the slit in the bottom dressing;

29 Figure 5 is a plan view of the transcutaneous device dressing slid in place with a  
30 catheter, such that the bottom dressing is in contact with a portion of the catheter protruding  
31 from the skin; and

32 Figure 6 is a plan view of transcutaneous device dressing folded such that the top

1 dressing is in contact with a portion of the catheter protruding from the skin.

## 2 **DESCRIPTION OF THE PREFERRED EMBODIMENTS**

### 3 Transcutaneous Device Dressing

4 The dressing in accordance with the invention includes at least one, and preferably at  
5 least two or three layers of medical dressing materials, laminated together by known means  
6 such as low temperature thermal fusing, stitching or, most preferably, ultrasonic welding. A  
7 three layer dressing in accordance with the invention is shown generally at 10 in Figure 1 to  
8 include a first layer 12, which will be skin facing in use, a second layer 14, which preferably  
9 forms an absorbent core, and a third layer 16. The layers 12, 14 and 16 are shown to be  
10 laminated together by ultrasonic welds 18 at intermittent locations across the dressing 10.

11 Figure 2 shows the dressing 10 to comprise a top dressing 20 and a bottom dressing  
12 22 formed from the three layers 12, 14 and 16. In Figure 2, the top and bottom dressings 20,  
13 22 are joined along a fold line 24, being formed from a unitary dressing 10. However, in  
14 accordance with this invention, the top and bottom dressings 20, 22 may be formed from  
15 separately, from same or different medical dressing materials. If the top and bottom dressings  
16 20, 22 are provided separately, the top dressing 20 may include an occlusive or semi-  
17 occlusive layer such as an adhesive film (not shown) in order to secure the dressing 10 in  
18 place, and retain moisture for activation of the anti-microbial material. A slit 26 is formed in  
19 the bottom dressing 22, preferably extending from the edge of the bottom dressing 22 which  
20 is parallel to the fold line 24, and terminating at a termination point 28 which is preferably  
21 about the center point of the bottom dressing 22.

22 The dressing 10 is shown in place against the skin 30 of a patient in Figure 3, with a  
23 catheter 32 protruding from the skin 30 at a penetration site 34. The dressing is held in place  
24 against the skin with an occlusive or semi-occlusive layer 36, such as adhesive tape or  
25 polyurethane film. The dressing is sized to cover a significant portion of the catheter 32 that  
26 protrudes from the skin 30, and not just the immediate skin area surrounding the penetration  
27 site. This aids in limiting infection, since bacteria are prevented from migrating along the  
28 catheter 32. A minimum dressing size will preferably provide at least 5 mm coverage of the  
29 protruding catheter 32, more preferably 1 - 5 cm coverage.

30 Depending on the size of the transcutaneous medical device, the termination point 28  
31 of the slit 26, may include additional cuts, preferably a cross-cut, or a penetrating hole (not  
32 shown), to allow the medical device to fit through the dressing, while still maintaining the

1 portions around the termination point in close contact with both the skin and protruding  
2 section of the medical device.

3 Figures 4, 5 and 6 demonstrate placement of the dressing 10 around a catheter 32,  
4 with the bottom dressing 22 sliding under the catheter 32 such that the lower surface 36 (see  
5 Figure 2) of the bottom dressing 22 contacts the patient's skin (not shown), while the upper  
6 surface 38 of the bottom dressing 22 contacts the catheter 32 protruding from the skin. Once  
7 the top dressing 20 is applied, by folding it over the bottom dressing 22, the lower surface 40  
8 (see Figure 2) of the top dressing 20 is in contact with the catheter 32 protruding from the  
9 skin. The upper surface 42 of the top dressing 20 is then covered with the occlusive or semi-  
10 occlusive layer 36, as shown in Figure 3. As shown in Figures 4 and 5, when the dressing 10  
11 is formed from a unitary dressing, the lower surface 40 of the top dressing 20 and the upper  
12 surface 40 of the bottom dressing 22, are one and the same layer, represented as layer 16 in  
13 Figure 1.

14 The lower and upper surfaces 38 and 40 of the bottom dressing 22, and at least the  
15 lower surface 42 of the top dressing 20 are provided with an anti-microbial material in order  
16 to limit infection. Anti-microbial materials for use with medical dressing materials are well  
17 known in the art. The anti-microbial material may be impregnated in one or more of the  
18 layers of the dressing 10, but will more preferably be provided as a thin film of an anti-  
19 microbial metal on those surfaces of the top and bottom dressings 20, 22 which will be skin  
20 or catheter facing once the dressing is in place. Alternatively, the anti-microbial material may  
21 be an antibiotic composition or a composition formed from an anti-microbial metal, as are  
22 well known in the art.

23 The preferred and alternate compositions of the layers 12, 14 and 16, together with the  
24 preferred anti-microbial metal coatings are set out in further detail below.

25 Dressing Materials

26 The first layer 12 of the dressing 10 is formed of a perforated, preferably non-adherent  
27 material which allows for fluids to penetrate or diffuse there through in either or both  
28 directions. The perforated material may be formed of a woven or non-woven, non-woven  
29 being preferred, fabric such as cotton, gauze, a polymeric net or mesh such as polyethylene,  
30 nylon, polypropylene or polyester, an elastomer such as polyurethane or polybutadiene  
31 elastomers, or a foam such as open cell polyurethane foam. Exemplary perforated, non-  
32 adherent materials useful for the dressing include non-woven meshes such as DELNET™

1 P530, which is a non-woven veil formed of high density polyethylene using extrusion,  
2 embossing and orientation processes, produced by Applied Extrusion Technologies, Inc. Of  
3 Middletown, Delaware, USA. This same product is available as Exu-Dry CONFORMANT  
4 2<sup>TM</sup> Wound Veil, from Frass Survival Systems, Inc., Bronx, New York, USA as a subset of  
5 that company's Wound Dressing Roll (Non-Adherent) products. Other useful non-woven  
6 meshes include CARELLE<sup>TM</sup> or NYLON 90<sup>TM</sup>, available from Carolina Formed Fabrics  
7 Corp., N-TERFACE<sup>TM</sup>, available from Winfield Laboratories, Inc., of Richardson, Texas,  
8 USA. Exemplary woven meshes may be formed from fibreglass or acetate, or cotton gauze.  
9 An exemplary hydrophilic polyurethane foam is HYPOL<sup>TM</sup>, available from W.R. Grace &  
10 Co., New York, NY, USA.

11 For ease of ultrasonic welding for lamination, at least one of the first and second  
12 layers 12, 14 is preferably formed from a polymeric material which is amenable to ultrasonic  
13 welding, that is which will melt on the application of localized heat and then fuse the layers  
14 together on cooling.

15 The second, absorbent layer 14 is formed from an absorbent material for holding  
16 sufficient moisture next to the skin in order to activate the anti-microbial metal coating, that  
17 is to cause release of ions, molecules, atoms or clusters of the anti-microbial metal in order to  
18 cause an anti-microbial effect. Preferably, the absorbent material is an absorbent needle  
19 punched non-woven rayon/polyester core such as SONTARA<sup>TM</sup> 8411, a 70/30  
20 rayon/polyester blend commercially available from Dupont Canada, Mississauga, Ontario,  
21 Canada. This product is sold by National Patent Medical as an American White Cross sterile  
22 gauze pad. However, other suitable absorbent materials include woven or non-woven  
23 materials, non-woven being preferred made from fibers such as rayon, polyester,  
24 rayon/polyester, polyester/cotton, cotton and cellulosic fibers. Exemplary are creped  
25 cellulose wadding, an air felt of air laid pulp fibers, cotton, gauze, and other well known  
26 absorbent materials suitable for medical dressings.

27 The third layer 16 of the dressing 10 is preferably formed of perforated, non-adherent  
28 material such as used in the first layer 12. This allows moisture penetration as sterile water  
29 and the like are added in order to activate the anti-microbial metal coating.

30 Additional layers (not shown) may be included between or above the first, second and  
31 third layers 12, 24, 16, as is well known in medical. Thus the use of the terms first, second  
32 and third layer, as used herein and in the claims is not meant to exclude such additional

1 layers.

2 The layers 12, 14, and 16 laminated together at intermittent spaced locations across  
3 the dressing 10 by ultrasonic welds 18. Ultrasonic welding is a known technique in the  
4 quilting art, and thus will not be discussed at length. Briefly, heat (generated ultrasonically)  
5 and pressure are applied to either side of the dressing 10 at localized spots through an  
6 ultrasonic horn so as to cause melting of at least one of the plastic materials in the first and  
7 second layers 12, 14, and the subsequent bonding together of the layers on cooling. The  
8 welds appear at localized circular spots and are preferably less than 0.5 cm in diameter. If the  
9 third layer 16 is present, the ultrasonic welding can be performed from either side of the  
10 dressing, and will bind all three layers 12, 14 and 16 together.

11 The use of ultrasonic welding of the layers at spaced locations has the advantage of  
12 retaining the absorbent and moisture penetration properties of the layers 12, 14, while  
13 retaining the conforming properties of the dressing. Edge seams, stitching and adhesives  
14 have the disadvantage of interfering with one or more of these desirable properties of the  
15 dressings. Furthermore, by spacing the welds 18 at intermittent locations across the dressing,  
16 the dressing 10 may be cut to smaller sizes, as needed, without causing delamination.

17 Preferred spacings of about 2.5 cm between welds allows the dressing to be cut down to  
18 about 2.5 cm sizes, while maintaining at least one weld to hold the laminated layers together.

#### 19 Anti-Microbial Coating

20 The dressing 10 of this invention preferably includes an anti-microbial coating formed  
21 from an anti-microbial metal. The coating is applied to one or more of the layers 12, 14, 16,  
22 but is most preferably applied at least to the first and third layers 12 and 16, so as to provide  
23 the anti-microbial effect both against the skin and against the transcutaneous medical device  
24 held between the top and bottom dressings 20, 22.

25 The coating is most preferably formed with atomic disorder in accordance with the  
26 procedures set out above and as described in US Patent 5,454,886, and WO98/41095, both to  
27 Burrell et al. Most preferably, the coating is formed as a multilayer anti-microbial coating  
28 having a top and a base layer, as set below, to produce an interference colour. In this way, the  
29 coating provides not only an anti-microbial effect to limit infection, but also acts as an  
30 indicator of activation of the dressing. As the top layer of the coating is activated with an  
31 alcohol or water-based electrolyte, such as sterile water or ethanol, even minor dissolution of  
32 the anti-microbial metal results in a detectable colour change, indicating that an anti-

1 microbial effect is being provided. If there is no colour change, additional moisture might be  
2 provided to the dressing by adding water, until a colour change is detected. Once activated,  
3 the dressing should be maintained in a moist condition by the addition of sterile water if  
4 necessary.

5 Sterilization

6 Dressings 10 with anti-microbial coatings of an anti-microbial metal formed with  
7 atomic disorder are preferably sterilized without applying excessive thermal energy, which  
8 can anneal out the atomic disorder, thereby reducing or eliminating a useful anti-microbial  
9 effect. Gamma radiation is preferred for sterilizing such dressings, as discussed in US Patent  
10 5,454,886.

11 It should be appreciated that the use of ultrasonic welding to laminate the layers of  
12 dressings with anti-microbial coatings formed from anti-microbial metals with atomic  
13 disorder is advantageous since it achieves bonding in localized spots and avoids applying heat  
14 to any significant portion of the dressing, thereby avoiding any significant reduction in the  
15 anti-microbial effect through annealing out of atomic disorder.

16 The sterilized dressings should be sealed in packaging which excludes light  
17 penetration to avoid additional oxidation of the anti-microbial coating. Polyester peelable  
18 pouches are preferred. The shelf life of anti-microbial dressings thus sealed is over one year.

19 Directions for Use of Dressings with Transcutaneous Devices

20 With transcutaneous devices such as flexible catheters, the dressing 10 is placed on  
21 the skin around the catheter 32 by passing the catheter 32 through the slit 26. The dressing 10  
22 is rotated, if needed, to ensure that slit 26 is roughly perpendicular to the long axis of the  
23 catheter 32, thus ensuring that the portion of the catheter 32 protruding from the skin is  
24 contacted by the upper surface 40 of the bottom dressing 22. The top dressing 20 is folded  
25 over the bottom dressing 22 (or placed over, if the top and bottom dressings are separate),  
26 such that the lower surface 42 of the top dressing 20 is in contact with the portion of the  
27 catheter 32 protruding from the skin. If the anti-microbial material is an anti-microbial metal  
28 coating, the dressing is then moistened with drops of sterile water or 70% ethanol, in order to  
29 activate the coating for release of anti-microbial metal species. The dressing 10 is then  
30 secured in place with an occlusive or semi-occlusive layer 36, such as an adhesive film,  
31 which keeps the dressing in a moist environment.

32 If the transcutaneous device is rigid, such as a temporary orthopedic pin, the bottom

1 dressing 22 is put in place as set out above, but the top dressing 20 is then folded and secured  
2 around the portion of the pin protruding from the skin, in a tent-like manner, since the pin  
3 generally protrudes at an angle normal to the skin surface.

4 Animal trials with the dressing of the present invention, carrying a bi-layer anti-  
5 microbial coating formed with silver having atomic disorder, manufactured as set out above  
6 and as described in greater detail in Example 3, have shown excellent results in controlling  
7 infection. In use, the dressings are kept moist, at 100% relative humidity. Adding sterile  
8 water initially to activate the anti-microbial metal coating is needed, and then as needed to  
9 maintain the dressing in a moist condition. Dressings may be changed as required for  
10 observation and cleaning, but need not be changed more frequently than every 7 days, and  
11 can provide an anti-microbial effect for a much longer period of time.

12 **Multilayer Anti-Microbial Materials With Interference Colour**

13 The dressings preferably include the anti-microbial metal coating formed with at least  
14 two metal layers, a base layer and a top layer over the base layer, so as to produce an  
15 interference colour, as set forth in WO98/41095. Both layers are partly reflective; the top  
16 layer is partly light transmissive. The top layer is a thin film containing at least one anti-  
17 microbial metal formed with sufficient atomic disorder such that the top layer, in contact with  
18 an alcohol or water based electrolyte, releases ions, atoms, molecules or clusters of the anti-  
19 microbial metal at a concentration sufficient to provide a localized anti-microbial effect on a  
20 sustainable basis. In this way, the top layer, in contact with the alcohol or electrolyte, will  
21 undergo a change in optical path length, either by a change in thickness resulting from some  
22 dissolution, or through a change in the refractive index of the top layer resulting from a  
23 change in the composition of a newly formed thin layer formed on the top layer. Either or  
24 both of these results are sufficient to cause a detectable colour change, thus providing an  
25 indicator that the top layer has been activated.

26 Both the base layer and the top layer are formed from a partly reflective material. In  
27 this way, at least a portion of the incoming light is reflected from the surface of the layer  
28 while another portion is transmitted through the layer. The top layer is partly light  
29 transmissive to allow incident light to reach the interface with the base layer. The top layer  
30 thus cannot approximate 100% reflectivity, such as in pure Al or Ag, or interference colours  
31 cannot be generated, as is well known in the art. The materials for the top and base layers  
32 should be balanced in their reflectances in order to generate an interference colour.

1 Generally, the top layer is deposited as a thin film having a thickness which maintains  
2 adequate transmittance to generate an interference colour. Furthermore, the refractive index  
3 for the materials in layers is different, accomplished by differences in their actual or effective  
4 compositions. For instance different materials in the two layers will result in the materials  
5 having different actual refractive indexes. However, if it is desired to make the layers from  
6 the same material, the layers can be deposited with different porosities or different  
7 levels/types of atomic disorder, in order to achieve different effective compositions, and thus  
8 different refractive indexes.

9 In this manner, incoming light reflects off the interface of the base and top layers.  
10 Incoming light reflects from the interface of the top layer with air, and interferes with the  
11 light reflected from the interface with the base layer so as to generate an "interference  
12 colour". The particular colour which is generated and its brightness will depend on the  
13 properties of the layers, most importantly on the composition of the layers, which determines  
14 its transmittance and absorption properties, along with its refractive index, and on the  
15 thickness of the layers. Generally, it is desirable to generate first and second order  
16 interference colours, by limiting the thickness of the base layer and top layers to minimize the  
17 number of internal reflections. First and second order interference colours are generally  
18 brighter than third and fourth order etc. colours, making them more aesthetically pleasing,  
19 more consistently reproducible in manufacturing, and more susceptible to detectable colour  
20 change on variations in thickness on dissolution of even a minor amount of the top layer.

21 The property which determines the particular colour which is generated is the  
22 effective optical thickness of the top layer, that is the product of the refractive index of the  
23 top layer material and the actual thickness of the top layer. Thus the colour which is desired  
24 can be altered by changing the actual thickness of the top layer or its refractive index.

25 Preferably, the material in the base layer is a reflective metal. Such metals are known  
26 in the art and include, for example one or more of the valve metals, e.g., Ta, Nb, Ti, Zr and  
27 Hf, as well as transition metals such as Au, Ag, Pt, Pd, Sn, Cu, V, W and Mo, or the metal Al.  
28 More preferably, the base material is formed from Ag, Au, Pt, Pd, Cu, Ta and Al. Use of a  
29 metal such as tantalum as the base layer may cause reduction of oxide containing materials in  
30 the top layer. To avoid this, a barrier layer (not shown), such as tantalum oxide formed by  
31 anodizing at least a portion of the top surface of the Ta metal, should be included above a  
32 tantalum layer. Preferred metals for the base layer are the anti-microbial metals Au, Ag, Pt,

1 Pd, Sn and Cu, more preferably Au, Pt and Ag, and most preferably Ag, in a partly reflective  
2 form.

3 The base layer may be formed by known techniques, such as the vapour deposition  
4 techniques of evaporation or physical vapour deposition. Preferably, the base layer is formed  
5 as a thin film by physical vapour deposition with atomic disorder, as set out below and in US  
6 5,454,889, in order to produce a sustainable anti-microbial effect when the base layer is  
7 ultimately exposed to an alcohol or water based electrolyte. The thickness of the base layer is  
8 generally not critical, provided that it is partly reflective. Preferred thicknesses will vary  
9 widely with the material composition and the desired colour. However, in that the layer is  
10 preferably a thin film formed by physical vapour deposition techniques, it should be at least  
11 about 25 nm thick to create a useful colour. To generate first and second order interference  
12 colours and to produce an anti-microbial effect, the base layer should be greater than 60 nm  
13 thick, more preferably 300 to 2500 nm thick, and most preferably 600 to 900 nm thick.

14 The top layer is formed of a partly reflective, partly light transmissive thin film  
15 containing at least one anti-microbial metal formed with atomic disorder so as to produce a  
16 sustainable anti-microbial effect, and ultimate colour change, when exposed to an alcohol or a  
17 water based electrolyte. The anti-microbial metal is preferably one or more of Ag, Au, Pt,  
18 Pd, Ir, Sn, Cu, Sb, Bi, and Zn in a partly reflective, partly transmissive form. More  
19 preferably, the anti-microbial metal is Ag, Au, Pt, Pd or Cu. The thickness of the top layer  
20 formed from these metals is preferably less than 400 nm in order to maintain the preferred  
21 level of light transmission. The desired thickness will vary with the composition of the top  
22 layer, and with the desired end colour and colour change. For first and second order  
23 interference colours, the thickness will generally be less than about 400 nm. More preferably,  
24 the thickness will range from 5 to 210 nm, most preferably from 10 to 100 nm.

25 The top layer may be a thin film of the base layer material, formed with a different  
26 refractive index for instance by altering the deposition conditions to change the porosity,  
27 composition and/or degree of atomic disorder in the layers.

28 When the base layer is itself formed from an anti-microbial metal with atomic  
29 disorder, the top layer may be provided as an in situ generated top layer by virtue of its  
30 thickness and/or composition changing on contacting an alcohol or water based electrolyte, so  
31 as to produce an interference colour which differs from the initial colour of the base layer.

32 Most preferably, the top layer is a thin film of a composite material formed by co-,

1 sequentially or reactively depositing an anti-microbial metal in a matrix with atoms or  
2 molecules of a different material to create atomic disorder in the matrix, in the manner set out  
3 below. The different material is selected from a) biocompatible metals, b) oxygen, nitrogen,  
4 hydrogen, boron, sulphur or halogens, or c) an oxide, nitride, carbide, boride, halide, sulphide  
5 or hydride of either or both of an anti-microbial metal or a biocompatible metal. Most  
6 preferably, the top layer material is a composite material containing silver, and one or both of  
7 silver oxide and atoms or molecules containing oxygen trapped or absorbed in the silver  
8 matrix. The term "silver oxide" is meant to include any oxide or mixture of oxides of silver.  
9 However, the top layer is preferably not formed solely of AgO and/or Ag<sub>2</sub>O, since the  
10 solubility of these materials is low for providing a useful anti-microbial effect.

11 Anti-Microbial Materials Containing Atomic Disorder

12 At least the top layer, and preferably also the base layer, is formed in a crystalline  
13 form from anti-microbial metals with atomic disorder so as to produce an anti-microbial  
14 effect. The production of atomic disorder through physical vapour deposition techniques is  
15 described in U.S. 5,454,886, and as outlined below.

16 The anti-microbial metal is deposited as a thin metallic film on one or more surfaces  
17 of the dressing 10, by vapour deposition techniques. Physical vapour techniques, which are  
18 well known in the art, all deposit the metal from the vapour, generally atom by atom, onto a  
19 substrate surface. The techniques include vacuum or arc evaporation, sputtering, magnetron  
20 sputtering and ion plating. The deposition is conducted in a manner to create atomic disorder  
21 in the coating as defined above. Various conditions responsible for producing atomic  
22 disorder are useful. These conditions are generally those which one has been taught to avoid  
23 in thin film deposition techniques, since the object of most thin film depositions is to create a  
24 defect free, smooth and dense film (see for example J.A. Thornton, supra). While such  
25 conditions have been investigated in the art, they had not been linked to enhanced solubility  
26 of the coatings so-produced prior to Applicants inventions.

27 The preferred conditions which are used to create atomic disorder during the  
28 deposition process include:

29 - a low substrate temperature, that is maintaining the surface to be coated at a  
30 temperature such that the ratio of the substrate temperature to the melting point of the metal  
31 (in degrees Kelvin) is less than about 0.5, more preferably less than about 0.35 and most  
32 preferably less than about 0.3; and optionally one or both of:

1                   - a higher than normal working (or ambient) gas pressure, i.e. for vacuum  
2 evaporation: e-beam or arc evaporation, greater than 0.01 mT, gas scattering evaporation  
3 (pressure plating) or reactive arc evaporation, greater than 20 mT; for sputtering: greater than  
4 75 mT; for magnetron sputtering: greater than about 10 mT; and for ion plating: greater than  
5 about 200 mT; and

6                   - maintaining the angle of incidence of the coating flux on the surface to be  
7 coated at less than about 75°, and preferably less than about 30°.

8                   The metals used in the coating are those known to release ions etc. having an anti-  
9 microbial effect, as set out above. For most dressings, the metal must also be biocompatible.  
10 Preferred metals include the noble metals Ag, Au, Pt, Pd, and Ir as well as Sn, Cu, Sb, Bi, and  
11 Zn or alloys or compounds of these metals or other metals. Most preferred is Ag or Au, or  
12 alloys or compounds of one or more of these metals.

13                   For economic reasons, the thin metal film has a thickness no greater than that needed  
14 to provide release of metal ions on a sustainable basis over a suitable period of time, and to  
15 generate the desired interference colour. Within the preferred ranges of thicknesses set out  
16 above, the thickness will vary with the particular metal in the coating (which varies the  
17 solubility and abrasion resistance), and with the degree of atomic disorder in (and thus the  
18 solubility of) the coating. The thickness will be thin enough that the coating does not  
19 interfere with the dimensional tolerances or flexibility of the device for its intended utility.

20                   The anti-microbial effect of the material so produced is achieved when the coating is  
21 brought into contact with an alcohol or a water based electrolyte, thus releasing metal ions,  
22 atoms, molecules or clusters. The concentration of the metal species which is needed to  
23 produce an anti-microbial effect will vary from metal to metal. Generally, anti-microbial  
24 effect is achieved in body fluids such as plasma, serum or urine at concentrations less than  
25 about 0.5 - 5 µg/ml.

26                   The ability to achieve release of metal atoms, ions, molecules or clusters on a  
27 sustainable basis from a coating is dictated by a number of factors, including coating  
28 characteristics such as composition, structure, solubility and thickness, and the nature of the  
29 environment in which the device is used. As the level of atomic disorder is increased, the  
30 amount of metal species released per unit time increases. For instance, a silver metal film  
31 deposited by magnetron sputtering at  $T/T_m < 0.5$  and a working gas pressure of about 7  
32 mTorr releases approximately 1/3 of the silver ions that a film deposited under similar

1 conditions, but at 30 mTorr, will release over 10 days. Films that are created with an  
2 intermediate structure (ex. lower pressure, lower angle of incidence etc.) have Ag release  
3 values intermediate to these values as determined by bioassays. This then provides a method  
4 for producing controlled release metallic coatings. Slow release coatings are prepared such  
5 that the degree of disorder is low while fast release coatings are prepared such that the degree  
6 of disorder is high.

7 For continuous, uniform coatings, the time required for total dissolution will be a  
8 function of film thickness and the nature of the environment to which they are exposed. The  
9 relationship in respect of thickness is approximately linear, i.e. a two fold increase in film  
10 thickness will result in about a two fold increase in longevity.

11 It is also possible to control the metal release from a coating by forming a thin film  
12 coating with a modulated structure. For instance, a coating deposited by magnetron  
13 sputtering such that the working gas pressure was low (ex. 15 mTorr) for 50% of the  
14 deposition time and high (ex. 30 mTorr) for the remaining time, has a rapid initial release of  
15 metal ions, followed by a longer period of slow release. This type of coating is extremely  
16 effective on devices such as urinary catheters for which an initial rapid release is required to  
17 achieve immediate anti-microbial concentrations followed by a lower release rate to sustain  
18 the concentration of metal ions over a period of weeks.

19 The substrate temperature used during vapour deposition should not be so low that  
20 annealing or recrystallization of the coating takes place as the coating warms to ambient  
21 temperatures or the temperatures at which it is to be used (ex. body temperature). This  
22 allowable  $\Delta T$ , that the temperature differential between the substrate temperature during  
23 deposition and the ultimate temperature of use, will vary from metal to metal. For the most  
24 preferred metals of Ag and Au, preferred substrate temperatures of -20 to 200°C , more  
25 preferably -10°C to 100°C are used.

26 Atomic order may also be achieved, in either or both of the base and top layers by  
27 preparing composite metal materials, that is materials which contain one or more anti-  
28 microbial metals in a metal matrix which includes atoms or molecules different from the anti-  
29 microbial metals.

30 The preferred technique for preparing a composite material is to co- or sequentially  
31 deposit the anti-microbial metal(s) with one or more other inert, biocompatible metals  
32 selected from Ta, Ti, Nb, Zn, V, Hf, Mo, Si, Al and alloys of these metals or other metal

1 elements, typically other transition metals. Such inert metals have a different atomic radii  
2 from that of the anti-microbial metals, which results in atomic disorder during deposition.  
3 Alloys of this kind can also serve to reduce atomic diffusion and thus stabilize the disordered  
4 structure. Thin film deposition equipment with multiple targets for the placement of each of  
5 the anti-microbial and inert metals is preferably utilized. When layers are sequentially  
6 deposited the layer(s) of the inert metal(s) should be discontinuous, for example as islands  
7 within the anti-microbial metal matrix. The final ratio of the anti-microbial metal(s) to inert  
8 metal(s) should be greater than about 0.2. The most preferable inert metals are Ti, Ta, Zn and  
9 Nb. It is also possible to form the anti-microbial coating from oxides, carbides, nitrides,  
10 sulphides, borides, halides or hydrides of one or more of the anti-microbial metals and/or one  
11 or more of the inert metals to achieve the desired atomic disorder.

12 Another composite material may be formed by reactively co- or sequentially  
13 depositing, by physical vapour techniques, a reacted material into the thin film of the anti-  
14 microbial metal(s). The reacted material is an oxide, nitride, carbide, boride, sulphide,  
15 hydride or halide of the anti-microbial and/or inert metal, formed in situ by injecting the  
16 appropriate reactants, or gases containing same, (ex. air, oxygen, water, nitrogen, hydrogen,  
17 boron, sulphur, halogens) into the deposition chamber. Atoms or molecules of these gases  
18 may also become absorbed or trapped in the metal film to create atomic disorder. The  
19 reactant may be continuously supplied during deposition for codeposition or it may be pulsed  
20 to provide for sequential deposition. The final ratio of anti-microbial metal(s) to reaction  
21 product should be greater than about 0.2. Air, oxygen, nitrogen and hydrogen are particularly  
22 preferred reactants.

23 The above deposition techniques to prepare composite coatings may be used with or  
24 without the conditions of lower substrate temperatures, high working gas pressures and low  
25 angles of incidence previously discussed. One or more of these conditions are preferred to  
26 retain and enhance the amount of atomic disorder created in the coating.

27 Examples

28 Example 1

29 This example shows the preparation of a bilayer anti-microbial silver coating on a  
30 dressing material. A high density polyethylene dressing, DELNET<sup>TM</sup> or CONFORMANT  
31 2<sup>TM</sup> was coated with a silver base layer and a silver/oxide top layer to generate a coloured  
32 anti-microbial coating having indicator value. The coating layers were formed by magnetron

1 sputtering under the conditions set out in Table 1.

2 Table 1

| <u>Sputtering Conditions:</u> | <u>Base Layer</u>           | <u>Top Layer</u>            |
|-------------------------------|-----------------------------|-----------------------------|
| Target                        | 99.99% Ag                   | 99.99% Ag                   |
| Target Size                   | 20.3 cm diameter            | 20.3 cm diameter            |
| Working Gas                   | 96/4 wt% Ar/O <sub>2</sub>  | 96/4 wt% Ar/O <sub>2</sub>  |
| Working Gas Pressure          | 40 mTorr                    | 40 mTorr                    |
| Power                         | 0.3 kW                      | 0.15 kW                     |
| Substrate Temperature         | 20°C                        | 20°C                        |
| Base Pressure                 | 3.0 X 10 <sup>-6</sup> Torr | 3.0 X 10 <sup>-6</sup> Torr |
| Anode/Cathode Distance        | 100mm                       | 100mm                       |
| Sputtering Time               | 7.5 - 9 min                 | 1.5 min                     |
| Voltage                       | 369 - 373 V                 | 346 V                       |

14 The resulting coating was blue in appearance. A fingertip touch was sufficient to  
 15 cause a colour change to yellow. The base layer was about 900 nm thick, while the top layer  
 16 was 100 nm thick.

17 A zone of inhibition test was conducted. Mueller Hinton agar was dispensed into  
 18 Petri dishes. The agar plates were allowed to surface dry prior to being inoculated with a  
 19 lawn of *Staphylococcus aureus* ATCC#25923. The inoculant was prepared from Bactrol  
 20 Discs (Difco, M.) Which were reconstituted as per the manufacturer's directions.  
 21 Immediately after inoculation, the coated materials to be tested were placed on the surface of  
 22 the agar. The dishes were incubated for 24 hr. at 37°C. After this incubation period, the  
 23 zone of inhibition was calculated (corrected zone of inhibition = zone of inhibition - diameter  
 24 of the test material in contact with the agar). The results showed a corrected ZOI of about 10  
 25 mm.

26 The coating was analyzed by nitric acid digestion and atomic absorption analysis to  
 27 contain 0.24 +/- 0.04 mg silver per mg high density polyethylene. The coating is a binary  
 28 alloy of silver (>97%) and oxygen with negligible contaminants, based on secondary ion  
 29 mass spectroscopy. The coating, as viewed by SEM, was highly porous and consisted of  
 30 equiaxed nanocrystals organized into coarse columnar structures with an average grain size of  
 31 10 nm. Silver release studies demonstrated that silver was released continuously from the  
 32 coating until an equilibrium concentration of about 66 mg/L was reached (determined by  
 33 atomic absorption), a level that is 50 to 100 times higher than is expected from bulk silver  
 34 metal (solubility < 1mg/L).

35 By varying the coating conditions for the top layer to lengthen the sputtering time to 2

1 min, 15 sec., a yellow coating was produced. The top layer had a thickness of about 140 nm  
2 and went through a colour change to purple with a fingertip touch. Similarly, a purple  
3 coating was produced by shortening the sputtering time to 1 min, to achieve a top layer  
4 thickness of about 65 nm. A fingertip touch caused a colour change to yellow.

5 Example 2

6 This example is included to demonstrate a multilayer transcutaneous device dressing  
7 in accordance with the present invention. High density polyethylene mesh dressing material  
8 DELNET™ or CONFORMANT 2™ dressing was coated with a bilayer blue anti-microbial  
9 coating as set forth in Example 1, using the sputtering conditions of Table 1. Two layers of  
10 this coated dressing material were placed above and below an absorbent core material formed  
11 from needle punched rayon/polyester (SONTARA™ 8411). With the silver coating on both  
12 the first and third layers, the dressing may be used with either the blue coating side or the  
13 silver side in the skin facing position. For indicator value, it might be preferable to have the  
14 blue coating visible. The three layers were laminated together by ultrasonic welding to  
15 produce welds between all three layers spaced at about 2.5 cm intervals across the dressing.  
16 This allowed the dressing to be cut down to about 2.5 cm size portions for smaller dressing  
17 needs while still providing at least one weld in the dressing portion.

18 The coated dressings were sterilized using gamma radiation and a sterilization dose of  
19 25 kGy. The finished dressing was packaged in sealed individually polyester peelable  
20 pouches, and has shown a shelf life greater than 1 year in this form. The coated dressings can  
21 be cut in ready to use sizes, such as 5.1 x 10.2 cm strips, and slits formed therein before  
22 packaging. Alternatively, the dressings may be packaged with instructions for the clinician to  
23 cut the dressing to size and form the desired length of the slit for the medical device.

24 Example 3

25 This animal study evaluated four prototype catheter dressings, one of which was in  
26 made in accordance with Example 2 above, the others being 3 cm disc shaped catheter  
27 dressings of laminated dressing materials, having a thickness less than about 1 mm, formed  
28 with a slit to their center to fit beneath the catheter, and being coated with a silver coating  
29 deposited as in Example 1. The silver coatings were prepared in a full scale roll coater under  
30 conditions to provide coatings having the same properties set out in Examples 2 and 3 above.

31 The prototype dressings were as follows:

32 1. Silver Catheter Dressing, prepared as in Example 2, with a top and a bottom

dressing sized 5.1 x 5.1 cm, with a 2.6 cm slit in the bottom dressing, as an example of this invention.

2. Silver Disc 1 - A 3 cm disc of the dressing material of Example 2, but used only as a flat disc beneath the catheter (i.e., with no top dressing)
3. Silver Disc 2 - A 3 cm disc of the dressing material which included a first layer of silver coated DELNET, as set out in Example 1, laminated to STATEX, AET, 8.0NP<sub>2</sub>-A/QW, which is a layer of 100% rayon on a polyurethane film, used as a flat disc beneath the catheter (i.e. with no top dressing)
4. Silver Foam Disc 3 - A 3 cm disc formed of three layers of silver coated high density polyethylene prepared as in Example 1, alternating with two layers of polyurethane foam, L-00562-6 Medical Foam, available from Rynel Ltd., Bootbay, Maine, USA, used as a flat disc beneath the catheter (i.e., with no top dressing).

Fifteen healthy New Zealand white rabbits weighing 2.6 to 2.9 kg were used.

Segments of polyurethane catheters (Arrow polyurethane indwelling central venous catheters, 16 Ga, from Arrow International, Inc., Reading, PA, USA, cut to 5 cm long) were implanted subcutaneously in the back of the rabbits. The rabbits were anesthetized with halothane (University of Calgary, LESARC SOP A6 - Life & Environmental Sciences Animal Resource Centre, Standard Operating Procedures). The dorsal thorax and abdomen were clipped and scrubbed with non-antibiotic soap. A scalpel was used to make a cut on the skin. A 5 cm long catheter segment was then inserted into subcutaneous tissue space perpendicular to the spine. Six catheters were implanted in each rabbit. The catheter sites were dressed with each of the prototype catheter dressings or control gauzes, such that the protruding portion of the catheter passed through the slit of the disc or dressing. In the case of the dressing of this invention, Silver Catheter Dressing, the top layer was placed over the catheter and pressed down so that the dressing surrounded the segment of the catheter protruding from the skin. The catheters were sutured to the skin. Three rabbits were dressed with each type of dressing or control dressing.

Bacterial challenges of each site were made by placing bacterial suspension-soaked gauzes (10 x 12.5 cm) on the tops of the dressings. In this inoculation technique the gauzes used were larger than the test dressings and were in contact with the heads of the catheters

1 which protruded above the dressings, as a result the gauzes provided sources of bacteria to the  
 2 surrounding skin, the catheter dressings and the catheter heads. Five milliliters of bacterial  
 3 suspension (*Staphylococcus aureus* ATCC 25923, grown in TSB (tryptic soy broth)  
 4 overnight, washed with PBS (phosphate buffered saline) and re-suspended in PBS,  
 5 concentration adjusted to  $10^7$  CFU/ml (colony forming unit)) was inoculated at each catheter  
 6 site. An occlusive tape was then placed over the dressing to ensure a moist environment  
 7 inside.

8 The rabbits were observed for seven days and then euthanized on Day 7. The skin  
 9 was dissected and the inside portion of catheter was carefully exposed. Catheter sections (1  
 10 cm) were cut from the proximal and distal sites to the skin entrance and collected in tubes  
 11 containing 2 ml of STS (0.4% sodium thioglycolate, 0.85% sodium chloride and 1% Tween<sup>TM</sup>  
 12 20). Adherent bacteria were recovered from the proximal and distal sites of the catheters by  
 13 sonication and vortexing. The solutions were plated on TSA plates using a drop-plate method  
 14 and bacterial counts were recorded.

15 During the whole test period, all dressings or discs remained in place, although some  
 16 curling and folding occurred on three of the Disc 1 type discs. The results of the colonization  
 17 rates and bacteria counts for the proximal and distal sites of the implanted catheters are  
 18 presented in Table 2, with means of n (shown in parentheses) samples. The numbers in  
 19 parenthesis following the colonization rates represent numbers of colonized/total catheters.

20 Table 2 Catheter Colonization Rates and Bacterial Recovery from Catheters

| Dressing Type            | Colonization Rate (%) | Bacterial Counts for the Proximal Site (CFU/cm) | Bacterial Counts for the Distal Site (CFU/cm) |
|--------------------------|-----------------------|---|---|
| Silver Catheter Dressing | 0 (0/18)              | 0   | 0   |
| Silver Disc 1            | 38.8 (7/18)           | $1.8 \times 10^3$ (n=7)                         | $5.8 \times 10^2$ (n=9)*                      |
| Silver Disc 2            | 47.1 (8/17)           | $4.6 \times 10^3$ (n=8)                         | $3.2 \times 10^2$ (n=6)                       |
| Silver Foam Disc 3       | 33.3 (6/18)           | $1.4 \times 10^3$ (n=6)                         | $3.0 \times 10^2$ (n=2)                       |
| Control                  | 94.4 (17/18)          | $7.6 \times 10^4$ (n=17)                        | $4.1 \times 10^3$ (n=11)                      |

28 \* Two distal sites had 50 CFU/cm (only one colony was found in one of the duplicate plates,  
 29 while the proximal sites of the same catheters had no bacteria). This may have been because  
 30 of contamination. These two sites were not included when the colonization rate was

1 calculated for this group.

2 The data showed that with gauze coverage, 94.4 % of the catheters were contaminated  
3 with bacterial counts averaging over  $10^4$  CFU/cm. With regard to the Silver Catheter  
4 Dressing of this invention, it completely prevented bacterial colonization. The disc type  
5 dressings, Discs 1, 2 and 3 reduced catheter contamination rates to 38.8%, 47% and 33.3 %,  
6 respectively. It is expected that these disc dressing materials would reduce catheter  
7 contamination to a sufficiently low rate if a top dressing of the same material was used with  
8 the discs, in accordance with the present invention.

9 All publications mentioned in this specification are indicative of the level of skill of  
10 those skilled in the art to which this invention pertains. All publications are herein  
11 incorporated by reference to the same extent as if each individual publication was specifically  
12 and individually indicated to be incorporated by reference.

13 The terms and expressions in this specification are, unless otherwise specifically  
14 defined herein, used as terms of description and not of limitation. There is no intention, in  
15 using such terms and expressions, of excluding equivalents of the features illustrated and  
16 described, it being recognized that the scope of the invention is defined and limited only by  
17 the claims which follow.

1      We claim:

2      1. A transcutaneous device dressing for use with a transcutaneous medical device which  
3      has punctured the skin of a patient and which has a portion of the medical device protruding  
4      from the skin, comprising:

5              a top and a bottom dressing, both being formed from a flexible material and having  
6      upper and lower surfaces, the lower surfaces being skin facing when the dressing is in use;

7              the bottom dressing having a slit formed therein extending from one edge inwardly to  
8      a termination point within the confines of the bottom dressing;

9              an anti-microbial material provided without the use of adhesives at the upper and  
10     lower surfaces of the bottom dressing, and at least at the lower surface of the top dressing;

11              whereby, in use, the bottom dressing is placed next to the skin, the slit allowing the  
12     bottom dressing to surround the puncture site such that the lower surface of the bottom  
13     dressing is in contact with the skin and the upper surface of the bottom dressing is in contact  
14     with a portion of the medical device protruding from the skin; and the top dressing is placed  
15     above the puncture site such that its lower surface is in contact with a portion of the medical  
16     device protruding from the skin, thereby exposing a portion of the medical device protruding  
17     from the skin from above and below to the anti-microbial activity of the anti-microbial  
18     material.

19      2. A method of dressing the puncture site of a transcutaneous medical device to limit  
20     infection by microorganisms from the surrounding skin and a portion of the medical device  
21     that protrudes from the skin of a patient, comprising:

22              providing a transcutaneous device dressing, comprising:

23              a top and a bottom dressing, both being formed from a flexible material and having  
24      upper and lower surfaces, the lower surfaces being skin facing when the dressing is in use;

25              the bottom dressing having a slit formed therein extending from one edge inwardly to  
26      a termination point within the confines of the bottom dressing; and

27              an anti-microbial material provided without the use of adhesives at the upper and  
28     lower surfaces of the bottom dressing, and at least at the lower surface of the top dressing;

29              sliding the bottom dressing in place next to the skin using the slit to allow the bottom  
30     dressing to surround the puncture site at the termination point such that the lower surface of  
31     the bottom dressing is in contact with the skin surrounding the puncture site and the upper  
32     surface of the bottom dressing is in contact with a portion of the medical device protruding

1 from the skin;

2 applying the top dressing above bottom dressing such that the lower surface of the top  
3 dressing is in contact with a portion of the medical device protruding from the skin;

4 depending on the anti-microbial material, applying a water or alcohol based  
5 electrolyte to the dressing to release the anti-microbial material; and

6 fixing the top and bottom dressings to the skin.

7 3. The dressing or method as set forth in claim 1 or 2, wherein:

8 the top and bottom dressings are formed from a unitary dressing and are joined  
9 together and divided by a fold line.

10 4. The dressing or method as set forth in claim 3, wherein:

11 the anti-microbial material is a coating of an anti-microbial metal applied to the upper  
12 and lower surfaces of the bottom dressing, and at least to the lower surface of the top  
13 dressing.

14 5. The dressing or method as set forth in claim 4, wherein the slit is formed from the  
15 edge of the bottom dressing which is parallel to the fold line.

16 6. The dressing or method as set forth in claim 5, wherein the top and bottom dressings  
17 are formed from multilayered, laminated dressing materials.

18 7. The dressing or method as set forth in claim 6, wherein the top and bottom dressings  
19 are formed from:

20 a first, skin facing layer formed of a perforated, non-adherent material;

21 a second layer laminated to the first layer, and being formed of an absorbent material;

22 and

23 a third layer laminated to one or both of the first and second layers.

24 8. The dressing or method as set forth in claim 7, wherein the anti-microbial metal  
25 coating is formed on the first and the third layers.

26 9. The dressing or method as set forth in claim 8, wherein the top and bottom dressings  
27 are sized so as to provide coverage of the portion of the medical device protruding from the  
28 skin of at least about 5 mm.

29 10. The dressing or method as set forth in claim 9, wherein the anti-microbial metal  
30 coating is a thin film containing at least one anti-microbial metal, said anti-microbial metal  
31 being formed with sufficient atomic disorder such that the thin film, in contact with an  
32 alcohol or water based electrolyte, releases ions, atoms, molecules or clusters of the anti-

1 microbial metal into the alcohol or water based electrolyte at a concentration sufficient to  
2 provide a localized anti-microbial effect on a sustainable basis.

3 11. The dressing or method as set forth in claim 10, wherein the anti-microbial metal  
4 coating comprises:

5 a base layer of a partly reflective material capable of generating an interference colour  
6 when covered with a partly reflective, partly light transmissive top layer;

7 a top layer formed over said base layer, said top layer being a partly reflective, partly  
8 light transmissive thin film containing at least one anti-microbial metal and having a  
9 thickness such that a first or second order interference colour is produced, said top layer  
10 having a refractive index different from that of the base layer, and anti-microbial metal being  
11 formed with sufficient atomic disorder such that the top layer, in contact with an alcohol or  
12 water based electrolyte, releases ions, atoms, molecules or clusters of the anti-microbial metal  
13 into the alcohol or water based electrolyte at a concentration sufficient to provide a localized  
14 anti-microbial effect on a sustainable basis.

15 12. The dressing or method as set forth in claim 11, wherein the material in the base layer  
16 is a metal selected from the group consisting of Ag, Au, Pt, Pd, Cu, Ta, Al and alloys or  
17 compounds of one or more of these metals, in a partly reflective form, and wherein the anti-  
18 microbial metal in the top layer is selected from the group consisting of Ag, Au, Pt, Pd, Ir,  
19 Sn, Cu, Sb, Bi, Zn, and alloys or compounds of one or more of these metals.

20 13. The dressing or method as set forth in claim 12, wherein the material in the base layer  
21 and the anti-microbial metal in the top layer is a metal selected from the group consisting of  
22 Au, Ag, Pt, Pd, and Cu in a partly reflective form, and is formed by vapour deposition with  
23 sufficient atomic disorder such that the top layer, in contact with an alcohol or water based  
24 electrolyte, releases ions, atoms, molecules or clusters of the anti-microbial metal into the  
25 alcohol or water based electrolyte at a concentration sufficient to provide a localized anti-  
26 microbial effect on a sustainable basis.

27 14. The dressing or method of claim 13, wherein the metal in the base and top layer is Ag,  
28 Pt or Au.

29 15. The dressing or method as set forth in claim 14, wherein the top layer is a thin film of  
30 a composite material formed by co-, sequentially or reactively depositing the anti-microbial  
31 metal by vapour deposition in a matrix with atoms or molecules of a different material to  
32 create atomic disorder in the matrix, said different material being selected from the group

1 consisting of biocompatible metals, oxygen, nitrogen, hydrogen, boron, sulphur or halogens,  
2 or an oxide, nitride, carbide, boride, halide, sulphide or hydride of either or both of an anti-  
3 microbial metal or a biocompatible metal.

4 16. The dressing or method as set forth in claim 15, wherein the biocompatible metal is  
5 selected from the group consisting of Ta, Ti, Nb, V, Hf, Zn, Mo, Si and Al.

6 17. The dressing or method as set forth in claim 15, wherein the anti-microbial metal is  
7 silver and said different material is one or both of silver oxide and atoms or molecules  
8 containing oxygen trapped or absorbed in the matrix.

9 18. The dressing or method as set forth in claim 17, wherein the top layer is less than 400  
10 nm thick, and the base layer is at least 25 nm thick.

11 19. The dressing or method as set forth in claim 18, wherein the top layer is between 5  
12 and 210 nm thick, and the base layer is at least 60 nm thick.

13 20. The dressing or method as set forth in claim 19, wherein the top layer is about 40 -  
14 160 nm thick and the base layer is at least about 300 nm thick.

15 21. The dressing or method as set forth in claim 10 or 20, wherein the first and optional  
16 third layers are formed from a non-woven, perforated, non-adherent high density  
17 polyethylene material.

18 22. The dressing or method as set forth in claim 21, wherein the second layer is formed  
19 from a non-woven, absorbent rayon/polyester material.

20 23. The method as set forth in claim 2, wherein the dressing is fixed in place with an  
21 occlusive or semi-occlusive layer which maintains the dressing in a moist condition.

22 24. The method as set forth in claim 23, wherein the occlusive or semi-occlusive layer is  
23 an adhesive film.

1/2

FIG. 1




FIG. 2








FIG. 3



2/2



# INTERNATIONAL SEARCH REPORT

I      onal Application No  
PCT/CA 01/00304

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61M25/02

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61M A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category * | Citation of document, with indication, where appropriate, of the relevant passages                 | Relevant to claim No. |
|------------|--|-----------------------|
| A          | US 4 324 237 A (BUTTARAVOLI PHILIP M)<br>13 April 1982 (1982-04-13)<br>abstract; figures<br>----   | 1, 3                  |
| A          | DE 38 07 944 A (BRAUN MELSUNGEN AG)<br>21 September 1989 (1989-09-21)<br>abstract; figures<br>---- | 1                     |
| A          | EP 0 780 138 A (BECTON DICKINSON CO)<br>25 June 1997 (1997-06-25)<br>claim 1; figures<br>----      | 1                     |
| A          | US 5 236 421 A (BECHER FRANK)<br>17 August 1993 (1993-08-17)<br>abstract; figures<br>----          | 1                     |
|            |  | -/-                   |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the International filing date but later than the priority date claimed

- \*T\* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

8 August 2001

Date of mailing of the international search report

14/08/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Kousouretas, I

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 01/00304

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|----------|---|-----------------------|
| A        | DE 27 48 882 A (RAVA ARNIS DR MED)<br>3 May 1979 (1979-05-03)<br>page 7, paragraph 5 – paragraph 7; figures<br>----   | 1                     |
| A        | US 3 918 446 A (BUTTARAVOLI PHILIP M)<br>11 November 1975 (1975-11-11)<br>cited in the application<br>column 3, line 30 -column 4, line 40;<br>figures<br>----                    | 1,3                   |
| A        | WO 98 41095 A (BURRELL ROBERT EDWARD<br>;PRECHT RODERICK JOHN (CA); WESTAIM<br>TECHNOLO) 24 September 1998 (1998-09-24)<br>cited in the application<br>the whole document<br>---- | 1,3-22                |

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Initial Application No  
PCT/CA 01/00304

| Patent document cited in search report |   | Publication date | Patent family member(s) |  | Publication date |
|--|---|------------------|-------------------------|--|------------------|
| US 4324237                             | A | 13-04-1982       | NONE                    |  |                  |
| DE 3807944                             | A | 21-09-1989       | NONE                    |  |                  |
| EP 0780138                             | A | 25-06-1997       | US 5686096 A            |  | 11-11-1997       |
|  |   |                  | CA 2191818 A            |  | 23-06-1997       |
|  |   |                  | JP 9182801 A            |  | 15-07-1997       |
| US 5236421                             | A | 17-08-1993       | DE 3643985 A            |  | 03-12-1987       |
|  |   |                  | AT 66623 T              |  | 15-09-1991       |
|  |   |                  | AU 612111 B             |  | 04-07-1991       |
|  |   |                  | AU 7437787 A            |  | 22-12-1987       |
|  |   |                  | CA 1320888 A            |  | 03-08-1993       |
|  |   |                  | CZ 8703822 A            |  | 17-07-1996       |
|  |   |                  | DD 257016 A             |  | 01-06-1988       |
|  |   |                  | DE 3772453 A            |  | 02-10-1991       |
|  |   |                  | DE 3772453 D            |  | 02-10-1991       |
|  |   |                  | WO 8707164 A            |  | 03-12-1987       |
|  |   |                  | DK 32888 A              |  | 25-01-1988       |
|  |   |                  | EP 0247571 A            |  | 02-12-1987       |
|  |   |                  | FI 880349 A, B,         |  | 26-01-1988       |
|  |   |                  | GR 3002617 T            |  | 25-01-1993       |
|  |   |                  | HR 920856 A             |  | 30-04-1995       |
|  |   |                  | HU 206051 B             |  | 28-08-1992       |
|  |   |                  | IE 60248 B              |  | 15-06-1994       |
|  |   |                  | JP 1500326 T            |  | 09-02-1989       |
|  |   |                  | NO 880300 A             |  | 25-01-1988       |
|  |   |                  | NZ 220465 A             |  | 27-11-1990       |
|  |   |                  | PH 25195 A              |  | 27-03-1991       |
|  |   |                  | PT 84957 A, B           |  | 01-06-1987       |
|  |   |                  | SI 8710970 A            |  | 31-08-1996       |
|  |   |                  | SK 382287 A             |  | 06-05-1998       |
|  |   |                  | YU 97087 A              |  | 31-10-1989       |
|  |   |                  | ZA 8703765 A            |  | 28-12-1988       |
|  |   |                  | KR 9005853 B            |  | 13-08-1990       |
| DE 2748882                             | A | 03-05-1979       | NONE                    |  |                  |
| US 3918446                             | A | 11-11-1975       | CA 1055351 A            |  | 15-05-1979       |
|  |   |                  | JP 50152582 A           |  | 08-12-1975       |
| WO 9841095                             | A | 24-09-1998       | AU 5978298 A            |  | 12-10-1998       |
|  |   |                  | BR 9808341 A            |  | 16-05-2000       |
|  |   |                  | CN 1250350 T            |  | 12-04-2000       |
|  |   |                  | EP 0984698 A            |  | 15-03-2000       |
|  |   |                  | HU 0003183 A            |  | 28-02-2001       |
|  |   |                  | PL 335403 A             |  | 25-04-2000       |
|  |   |                  | ZA 9801557 A            |  | 03-09-1998       |